BioCryst Pharmaceuticals (BCRX)
(Real Time Quote from BATS)
$6.35 USD
-0.31 (-4.66%)
Updated May 23, 2024 10:20 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 1 - 20 ( 174 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Can Continue Near-Term Growth Strategy - Oral Differentiation; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for BCRX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biocrysts Structure-Based Drug Design Reflective of the Next Chapter of the Complement Mediated Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Near-Term Growth Strategy and Upside From Drug Discovery RD Day; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Orladeyo Growth Trajectory Continues to Define Near-Term; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Growth and Global ScopeSetting Foundation For Broader Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Expansion Met With Separate BCX10013 Pipeline Questions; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
BCX10013 Reflects Nimble Pivot For Complement Pipeline; Data Expected 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Whats Next? Considerations for the Complement-Mediated Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
FDA Lifts BCX9930 Partial Clinical Hold While Orladeyo Delivers in HAE
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Tale of Two Cities-As Orladeyo Expands, BCX9930 Re-Evaluates Dosing Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Expansion Within Oral HAE, and BCX9930 Pipeline in a Molecule Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Asserts HAE Positioning - Planting Flag for Oral Prophylaxis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Launch Reflects Oral Demand-Global HAE Upside on Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Impetus Supports Demand for Oral HAE Prophylactic; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Off to the Races, Along With Pivotal PNH Trials Expected 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Spotlight On BXC9930, Early Success for Factor D Inhibition; PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Three-Pronged Commercial Strategy With BCX9930 in its Wake
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A